Table 4.

Soluble TNF-Rs and Chromogranin A in ECD patients with/without cardiovascular involvement.

	sTNF-RI (ng/mL)	sTNF-RII (ng/mL)	CgA (ng/mL)
ECD w CV (n = 8)	4.41 ± 0 .99**	4.22 ± 0 .84*	217.66 ± 38 .29***
ECD w/o CV (n = 9)	4.55 ± 1 .04***	5.30 ± 1 .05***	84.36ns ± 21 .48
HD (n = 20)	1.21 ± 0 .09	1.83 ± 0 .10	35.44 ± 1 .72

Results are mean ± SEM of soluble TNF Receptor (sTNF-R) I and II, and Chromogranin A (CgA) concentrations in plasma from ECD patients with or without cardiovascular involvement (CV) and from Healthy Donors (HD), as determined by ELISA. Statistical significance between ECD patients and controls was assessed by ANOVA.

^*statistically significant at p < 0 .05.

^**statistically significant at p < 0 .01.

^***statistically significant at p < 0 .001.

^n.s. = not significant.